SCHEMBL14814023

SCHEMBL14814023

O=C(O)c1cccc(CN2CCC(=C3c4ccccc4CCc4ccccc43)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTAFR P25105 2/20 0.48
▸ FNTA P49354 2/20 0.46
▸ FNTB P49356 2/20 0.46
▸ SETD7 Q8WTS6 1/20 0.45
▸ HRH1 P35367 5/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ FAAH O00519 1/20 0.38
▸ KCNH2 Q12809 3/20 0.38
▸ CHRM2 P08172 2/20 0.38
▸ HTR1A P08908 2/20 0.38
▸ CHRM1 P11229 2/20 0.38
▸ DRD2 P14416 2/20 0.38
▸ HTR2A P28223 2/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ ADRA1A P35348 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14813616 0.88 KCNH2 (0.49) PTAFRFNTAFNTBSETD7HRH1
SCHEMBL14825801 0.85 HRH1 (0.49) PTAFRFNTAFNTBSETD7HRH1
SCHEMBL14825551 0.83 KCNH2 (0.55) PTAFRHRH1CYP2D6KCNH2PRMT5
SCHEMBL14825568 0.83 HRH1 (0.46) FNTAFNTBHRH1KCNH2CNR1
SCHEMBL2821305 0.79 KDM4E (0.53) FAAHCNR1
SCHEMBL22424947 0.79 KDM4E (0.53) FAAHCNR1
SCHEMBL14825786 0.79 HRH1 (0.72) PTAFRFNTAFNTBHRH1KCNH2
SCHEMBL14825793 0.78 HRH1 (0.43) PTAFRFNTAFNTBSETD7HRH1
SCHEMBL14827208 0.77 KDM4C (0.57) PTAFRFNTAFNTBSETD7HRH1
SCHEMBL465886 0.77 GNE (0.55) CYP2D6FAAHCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 PTAFR 2062/4885FNTA 4648/4885FNTB 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback